Effectiveness of Intravenous Tranexamic Acid in Primary Cerebral Hemorrhage for Prevention of Hematoma Progression: Protocol for a Randomized, Double Blind Placebo-controlled Trial
Cerebral Hemorrhage
About this trial
This is an interventional treatment trial for Cerebral Hemorrhage focused on measuring double blind randomized trial, spontaneous intracerebral hemorrhage, tranexamic acid
Eligibility Criteria
Inclusion Criteria:
- All patients presenting to the emergency department with symptom of hemorrhagic stroke within 24 hours from onset of symptom or last seen well.
- Patient who had a follow up
Exclusion Criteria:
- Glasgow coma scale <9 after resuscitation (as this can lead to biasness; requires surgery)
- Contraindication to tranexamic acid,
- Hemorrhagic stroke secondary to trauma,
- Hemorrhage was caused by coagulopathy
Sites / Locations
- KMC Teaching Hospital, Kathmandu, NepalRecruiting
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
tranexamic acid
Sodium Chloride
Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours
Four 5ml solution of either tranexamic acid 500mg or sodium chloride 0.9% are distributed which cannot be differentiated from the appearance. Loading dose of trial (1g of tranexamic acid in 10ml) or placebo (10 ml of sodium chloride 0.9%) is mixed in 100ml sodium chloride 0.9% and given over 10 minutes. Maintenance dose of trial or placebo mixed in 500ml sodium chloride 0.9% is given over 8 hours